The UK and US have hammered out a key commercial pact that will maintain no import taxes on UK drug exports being sold in the US market.
Agreement Details of the Pact
As part of the deal, the UK has committed to increase spending on drugs through the public health system. This pledge ensures that tariffs on these key products will remain at nothing for a period of 36 months.
This development is in response to previous statements to hike tariffs on patented drug imports, with potential rates discussed up to one hundred percent.
"This agreement with the Britain reinforces the global environment for new treatments and brings much-needed equity to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Impact
Medicines are one of the the United Kingdom's largest export categories to the America, which is easily the largest destination for leading British pharmaceutical firms.
Trade data show that in the 12 months leading up to September, the UK exported pharmaceutical products totaling billions to the US. This figure represented a significant portion of total UK exports in that span.
"This agreement safeguards jobs, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for medical research," a government official remarked.
Detailed British Pledges
The agreement involves several notable changes from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. Last year, rebates exceeded 20%.
Recent Tensions
The pact takes place against a protracted row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
This friction were heightened by assertions that American patients were paying a premium for the equivalent treatments than patients in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or scrapped, while major investments have been announced toward US facilities.
A senior figure acknowledged that the NHS must invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a share of its total funding over the past decade.
